No Data
Repare Therapeutics Analyst Ratings
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
Repare Therapeutics' Individualised Anaemia Management Trial Shows Promise
Repare Therapeutics Presented Updated Data Highlighting The Benefits Of Its Individualized Schedule For Managing Anemia In Phase 1 MYTHIC Trial, Which Treated Patients With The Combination Of Lunresertib And Camonsertib
No Data
No Data